22nd International AIDS Conference

Download All
July 23-27, 2018; Amsterdam, The Netherlands
Engage in this scientific analysis of AIDS 2018, with downloadable slides and expert faculty commentary on key HIV prevention and treatment studies.


Capsule Summaries

Doravirine treatment associated with decreased impact on lipids vs darunavir/ritonavir and low rate of emergent resistance.

Released: July 25, 2018

Week 24 virologic suppression rates numerically lower in patients with high baseline HIV-1 RNA levels, very low baseline CD4+ cell counts.

Released: July 30, 2018

Observations from patients with delayed switch to DTG plus RPV at Week 52 confirm safety and efficacy findings of primary analysis.

Released: July 31, 2018

Mutation associated with resistance to lamivudine and emtricitabine did not appear to affect efficacy of switch strategy.

Released: July 25, 2018

Dual-agent regimen well tolerated with high efficacy rate and no treatment-emergent resistance.

Released: July 26, 2018

Unplanned analysis showed nearly 7-fold increase in absolute risk for NTDs vs exposure to other ART at conception or during pregnancy.

Released: July 27, 2018

Open-label prospective cohort study of PrEP use among Parisian MSM finds high rate of correct use with both dosing strategies and zero incidence of HIV infection.

Released: July 27, 2018

Within-couple HIV transmission risk for serodifferent MSM comparable to that seen in heterosexual couples

Released: July 27, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
ViiV Healthcare
Janssen Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings